In accordance with Chapter 2, Section 10 c of the Finnish Securities
Market Act, Orion Corporation publishes an Annual Summary of the
stock exchange releases and announcements published by the company in
2007. The releases and announcements are available on the internet
website of Orion Corporation, at www.orion.fi/investors. Orion points
out that part of the information in the releases can have become
out-dated.
Stock Exchange Releases in 2007
24.01.2007 Change in the Executive Management Board of the Orion
Group as of 1 February 2007
24.01.2007 Share-based incentive plan for ca. 30 key persons in
Orion
29.01.2007 Recommendation by the Nomination Committee concerning
Board of Directors to be elected by the AGM of Orion
Corporation
06.02.2007 Bulletin of Orion Corporation Financial Statements for 1
July - 31 December 2006
06.02.2007 Orion Group Financial Review (proforma) 1-12/2006
06.02.2007 Orion updates progress with Simdax (i.v. levosimendan):
06.02.2007 Matters to be handled at Orion's AGM on 2 April 2007
01.03.2007 Orion Group Annual Report 2006 published
08.03.2007 Amendment to the Annual Report 2006 of Orion Corporation
concerning holdings of Board members
02.04.2007 Decisions by the AGM of Orion Corporation on 2 April 2007
02.04.2007 Jukka Ylppö Vice Chairman of the Board of Directors of
Orion Corporation. Compositions of Board committees
25.04.2007 Orion's partner discontinues development of levosimendan
(Simdax) in the US
25.04.2007 Orion Group Interim Report 1-3/2007
06.08.2007 Orion Group Interim Report 1-6/2007
06.08.2007 Decision of the Board of Directors of Orion on
repurchasing own shares
13.08.2007 Orion comments on ANDA filing of generic entacapone
(Orion's proprietary drug Comtan®) in the United States
11.09.2007 New President and CEO for Orion Corporation as of 1
January 2008
13.09.2007 Orion sues generic drug companies in the U.S. to enforce
patents for entacapone (Orion's proprietary drug Comtan®)
01.10.2007 Orion comments on ANDA filing of generic versions of
Orion's proprietary drug Stalevo® in the United States
24.10.2007 Orion Group Interim Report 1-9/2007
24.10.2007 Orion Corporation's publication schedules for financial
reporting in 2008
24.10.2007 Composition of the Nomination Committee of Orion
Corporation
13.11.2007 Orion sues Sun Pharmaceuticals in the U.S. to enforce a
patent for Stalevo®
15.11.2007 Appointments into Orion's Executive Management Board as
of 1 January 2008
27.11.2007 Announcement by Orion Corporation in accordance with
section 10 of chapter
2 of the Finnish Securities Market Act
Stock Exchange Announcements 2007
18.01.2007 223,000 Orion A-shares converted into B-shares
26.01.2007 70,000 Orion A-shares converted into B-shares
19.04.2007 Changes in Orion's Articles of Association entered in the
Trade Register
on 19 April 2007
26.04.2007 905,839 Orion A-shares converted into B-shares
21.05.2007 532,051 Orion A-shares converted into B-shares
21.06.2007 335,315 Orion A-shares converted into B-shares
06.07.2007 100,000 Orion A-shares converted into B-shares
31.08.2007 398,000 Orion A-shares converted into B-shares
07.11.2007 171,347 Orion A-shares converted into B-shares
17.12.2007 260,000 Orion A-shares converted into B-shares
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO Senior VP, Corporate Functions
ABOUT ORION
Orion is dedicated to treating and preventing disease by discovery
and developing innovative medicinal treatments. In 2007, Orion
generated net sales of EUR 683.6 million, invested EUR 97.6 million
in research and development and employed approximately 3,160 people.
Orion corporate headquarters are in Espoo, Finland. For more
information, please visit: http://www.orion.fi/english/.
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi
Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2007
| Source: Orion